Stony Brook Cancer Center

Summary

Stony Brook Cancer Center is a medical facility located in Stony Brook, New York. This center is recognized for care of Lung Cancer, Leukemia, Bladder Cancer, Lymphoma, Cancer and other specialties. Stony Brook Cancer Center is involved with conducting 58 clinical trials across 106 conditions. There are 7 research doctors associated with this hospital, such as Minsig Choi, Amna Sher, Roger S. Keresztes, and Lea Baer, MD.

Top PIs

Clinical Trials running at Stony Brook Cancer Center

Acute Myeloid Leukemia

Ovarian Cancer

Leukemia

Acute Myelogenous Leukemia

Cancer

Lymphoma

NPM1 Mutation

Kabuki Syndrome

Myeloid Leukemia

Mixed Mullerian Tumor

Ziftomenib Combinations

for Acute Myeloid Leukemia

Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with certain genetic alterations. This protocol has 3 separate arms that will investigate the benefits and risks of adding ziftomenib to standard-of-care (SOC) drug treatments in patients who have AML with certain genetic mutations. Both newly diagnosed and relapsed refractory patients with AML will be assigned to different cohorts based on specific study criteria and physician discretion. The purpose of this study is to assess the safety, tolerability, and early signs of efficacy of ziftomenib in combination with SOC drugs to treat AML.

Recruiting

1 award

Phase 1

Ziftomenib Combinations

for Acute Myeloid Leukemia

The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.

Recruiting

1 award

Phase 1

9 criteria

Leukemia Stem Cell Markers

for Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a malignant disorder of the bone marrow and the most common form of acute leukemia in adults. Patient with AML have the shortest survival compared to other forms of leukemia. In the past 6 years, several new therapies have been approved. Biomarkers are in urgent need to guide therapeutic regimen selection in order to maximize the benefit of available therapies and minimize treatment toxicity. Current standard practice is to perform bone marrow biopsy at end of treatment cycle (each cycle around 28 days), and based on bone marrow finding, to decide further treatment plan. It is invasive and time consuming. In this study investigators will study whether tracking leukemia stem cells (LSC) in peripheral blood during early treatment cycle may provide a non-invasive method to predict therapeutic outcome at end of treatment cycle. A retrospective study found that LSC fractional change, defined by two LSC markers, named CLL1 and CD45RA, is highly correlated with therapeutic outcome. Further more, CLL1 and CD45RA positive LSC fraction demonstrates a high concordance between bone marrow and peripheral blood, offering the opportunity to track CLL1 and CD45RA positive LSC fraction non-invasively in peripheral blood during treatment. This pilot study will allow the investigators to decide whether testing CLL1 and CD45RA positive LSC in peripheral blood during leukemia treatment is feasible in clinical practice. This result will lay the foundation for designing future trials using CLL1 and CD45RA positive LSC fractional change to optimize therapeutic strategy for patients with AML.

Recruiting

1 award

N/A

3 criteria